Physician profile
Michael Boyle
NPI 1629625603
$3,401.40
in general payments reported to CMS, 2019-2025
18 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $163 · 2023: $921 · 2024: $1,608 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.72 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.53 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $445.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $367.98 | 2021-2025 | Brilinta, Andexxa, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $337.54 | 2023-2025 | Eliquis, Camzyos |
| Amgen INC. | $333.89 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $219.42 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $200.53 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $175.39 | 2023-2025 | Verquvo |
| Scpharmaceuticals INC. | $163.08 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $132.88 | 2024 | Arcalyst |
| Medtronic, INC. | $127.66 | 2023-2025 | Aurora Ev-Icd Mri Surescan, Linq II |
| Janssen Pharmaceuticals, INC | $74.61 | 2023-2024 | Xarelto |
| Novo Nordisk INC | $70.94 | 2021-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.35 | 2023-2024 | Lifevest |
| Esperion Therapeutics, INC. | $48.69 | 2023-2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43.74 | 2021 | |
| Avanir Pharmaceuticals, INC. | $39.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.